Azosemide

Summary

Azosemide (CHEMBL1097235) is a phase-3 clinical-stage small-molecule loop diuretic.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Clinical trials: 1
• Chemistry: 370.8 Da · C12H11ClN6O2S2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1097235
Name	Azosemide
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	2273
ChEBI	CHEBI:31248
Molecular formula	C12H11ClN6O2S2
Molecular weight	370.8
InChIKey	HMEDEBAJARCKCT-UHFFFAOYSA-N

SMILES: C1=CSC(=C1)CNC2=CC(=C(C=C2C3=NNN=N3)S(=O)(=O)N)Cl

IUPAC name: 2-chloro-5-(2H-tetrazol-5-yl)-4-(thiophen-2-ylmethylamino)benzenesulfonamide

ChEBI definition: A sulfonamide that is benzenesulfonamide which is substituted at positions 2, 4, and 5 by chlorine, (2-thienylmethyl)amino and 1H-tetrazol-5-yl groups, respectively. It is a diuretic that has been used in the management of oedema and hypertension.

Pharmacological roles (ChEBI): loop diuretic.

Also known as: Azosemid, Azosemida, Azosemide, Diart, Luret, SID50125934, AZOSEMIDE, SID144206352, SID170465933, azosemide

Patent coverage: 1,504 distinct patent families (5,317 SureChEMBL compound mentions), from 3 matched compound structure(s). One matched structure accounts for 5,153 (97%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 3 (assay-derived). Sample: cGMP-inhibited 3’,5’-cyclic phosphodiesterase 3A, 3’,5’-cyclic-AMP phosphodiesterase 4D, Prostaglandin G/H synthase 1.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 3 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
PDE4D	5.11	AC50	7800	nM	CHEMBL_ACT_25184951

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
PHASE4	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00355667	PHASE4	COMPLETED	Comparison of Long- and Short-acting Diuretics in Congestive Heart Failure

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).